Faster answers at the bedside.

A point-of-care diagnostic for methotrexate measurement — results in under 10 minutes, no lab required.

Learn More Learn More

Overcoming the challenges of MTX measurement

Currently, blood analysis of methotrexate for high-dose oncology therapy requires immunoassays in hospital labs with specialized equipment and trained technicians — adding cost, time, and complexity. We're developing a low-cost, simple-to-use diagnostic in the point-of-care format.

See the Product See the Product

How it works

Collect 40 µl whole blood

Using a fixed volume pipet, collect a small whole blood sample — no centrifuge or special preparation needed.

Apply to the lateral flow device

Add the sample and buffer to the lateral flow device. The double antibody system begins detecting methotrexate immediately.

Read quantitative results in ≤ 10 minutes

Place the off-the-shelf digital reader onto the device. Remove and record results — all at the bedside.

No cross-reactivity

Unlike competitors with 20–100% DAMPA cross-reactivity, our double antibody system measures methotrexate only.

Results in ≤ 10 minutes

Bedside results without the 1.5–2 hour wait of traditional immunoassays. Faster answers when they matter most.

Simple enough for any healthcare professional

No specialized technician required. Five steps, no centrifuge, no serial dilution — just collect, apply, and read.

Point-of-Care
≤ 10 Minutes
No Cross-Reactivity
Bedside Testing

Interested in partnering?

We're looking for clinical collaborators, distribution partners, and investors.

Contact Us →